Companion Diagnostic Technologies Companies Market Position Advancements, Value Creation, Cross-border Expansion, Patent Expansions, Financial Performance Evaluation, Risk Mitigation, Licensing and Monetization, Efficiency Metrics

Companion Diagnostic Technologies Manufacturers and Market Growth

The companion diagnostic technologies market was estimated at US$ 2.78 billion in 2023 and is projected to grow to US$ 9.06 billion by 2034, rising at a compound annual growth rate (CAGR) of 11.34% from 2024 to 2034.

Top Companies in the Companion Diagnostic Technologies Market

• Agilent Technologies, Inc.
• Abbott Laboratories
• Becton, Dickinson and Company
• BioGenex
• Bristol Myers Squibb
• Danaher Corporation
• Foundation Medicine
• Myriad Genetics, Inc.
• Qiagen NV
• Quest Diagnostics
• Servier Pharmaceuticals
• Siemens Healthineers
• Sysmex Corp
• Tempus Technologies
• Thermo Fisher Scientific

Latest Announcements by Industry Leaders

Randy Evans, Vice President of Medical Affairs at BD Biosciences, commented that several companies should collaborate during the early development stage to achieve strategic harmony among industry players and align with the mandates of external regulatory authorities. He also stated that CDx can provide a competitive advantage for biopharma as the number of therapeutic options increases. Additionally, using a multimodal approach (e.g., genomic and proteomic) could lead to even better outcomes by enabling a more personalized approach.

Recent Developments in the Companion Diagnostic Technologies Market

• In October 2024, Thermo Fisher Scientific announced that it received US FDA approval for Oncomine, an in vitro diagnostic test, as a companion diagnostic in grade 2 IDH-mutant glioma. It is approved for use along with Servier Pharmaceuticals’ Voranigo (vorasidenib) tablets.
• In January 2024, ARUP Laboratories announced the first infusion of FDA-approved Roctavian, a gene therapy, with the AAV5 DetectCDx. The CDx kit involves a qualitative in vitro diagnostic test that uses a bridging immunoassay and electrochemiluminescence to determine whether anti-AAV5 antibodies are present in the blood plasma of a person with hemophilia A.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com